Press Release Details
Twist Bioscience Launches Long Oligos to Fuel Drug Development, DNA Data Storage and Gene Editing Research
-- Oligonucleotides up to 300 Bases with Exceptionally Low Error Rate –
-- Longest Commercial Oligonucleotide Offering Available Today --
Historically, making oligos longer than 150-200 bases has been extremely difficult due to chemical reaction inefficiencies. The addition of each base in the sequence introduces the risk of error because of the complex chemistry required to complete the synthesis. Twist has developed a proprietary way to make oligos up to 300 bases, with an industry-leading error rate as low as 1:1500 nucleotides.
“This new product launch provides Twist with a competitive advantage not only in oligo pool products, where longer oligos are useful in drug discovery and development, but also in data storage, where longer pieces of DNA can store more digital data per strand. In addition, longer oligos are uniquely enabling for certain CRISPR gene editing and protein engineering applications, where researchers can substantially increase their productivity. We believe there are additional applications where longer oligos will lead to more robust research discoveries, and we’re excited to be a part of pushing this science further,” said Emily M. Leproust, Ph.D., CEO and co-founder of
With this technical achievement and commercial product launch spearheaded by
“Synthesis of long oligonucleotides at scale requires significantly optimized engineering solutions to prevent errors including deletions, substitutions, insertions and fragmentations, which typically compound substantially with longer pieces of DNA,” commented Mr. Weiss. “Having been integrally involved in the DNA synthesis industry for 25 years, achieving this commercial milestone in a production environment is a true testament to the strength of the team and the robust technology.”
For more information about long oligonucleotides, please visit: https://www.twistbioscience.com/products/oligopools.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products